Induced Hepatocyte Differentiation via Conditioned Medium

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are inadequate for efficiently differentiating trophoblast stem cells into induced hepatocytes in vitro, lacking effective protocols for replicating the complex processes of liver development and function.

Innovation Solution

A method involving a conditioned medium with fibroblast growth factor (FGF), a steroid (such as dexamethasone), and a cytokine (like oncostatin M) is used to induce trophoblast stem cell differentiation into induced hepatocytes, mimicking the stages of liver development and expressing relevant biomarkers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional differentiation methods are used, then trophoblast stem cells can be differentiated into hepatocyte-like cells, but the efficiency and functional maturity of the induced hepatocytes are insufficient

Engineering Contradiction:

Improvedifferentiation efficiencyVSAvoidhepatocyte functional maturity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The differentiation process is divided into distinct sequential stages: definitive endoderm specification (using FGF and miR-124a modulation), hepatic endoderm formation (adding retinoic acid and HGF), and hepatoblast/hepatocyte maturation (adding oncostatin M and other cytokines). Each stage uses specific biomarkers to monitor progression, ensuring efficient and functionally mature hepatocyte induction.

Inventive Principle:

Principle #1Segmentation

2Reliability

If complex liver development processes are replicated in vitro, then induced hepatocytes can achieve primary hepatocyte-like characteristics, but the protocol complexity and time required increase significantly

Engineering Contradiction:

Improvehepatocyte functional characteristicsVSAvoiddifferentiation protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The protocol begins with FGF treatment to upregulate miR-124a and initiate definitive endoderm specification before adding other factors. This preliminary action establishes the correct developmental trajectory early, simplifying subsequent steps and reducing overall protocol complexity while maintaining high functional maturity.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The protocol systematically changes chemical parameters (adding specific growth factors, cytokines, and small molecules at defined concentrations and time points) to guide differentiation through each developmental stage. This controlled parameter manipulation achieves complex hepatocyte maturation through a series of manageable, standardized steps.

Inventive Principle:

Principle #35Parameter changes

3Manufacturing precision

If trophoblast stem cells are differentiated using extended culture periods, then more mature hepatocyte characteristics are achieved, but the time required for differentiation increases

Engineering Contradiction:

Improvehepatocyte maturation levelVSAvoiddifferentiation time

Core Design Contradiction:

Manufacturing precisionVSLoss of time

Solution Approach 1:

The differentiation protocol uses periodic addition of specific factors at defined time intervals: FGF (days 0-2), retinoic acid and HGF (days 2-4), oncostatin M (days 4-6), and final maturation factors (days 6-14). This periodic action accelerates maturation by providing optimal signals at critical developmental windows, reducing total time while achieving high maturity levels.

Inventive Principle:

Principle #19Periodic action

Data Source

PatentUS20230338431A1Human hepatocytes and uses thereof

Publication Date: 2023.10.26 ACCELERATED BIOSCIENCES CORP

AI summary

Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.